New diabetes clinical trial: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Published on: April 07, 2023 at 11:00AM
Conditions:   Type 2 Diabetes;   Obesity;   Overweight or Obesity;   Overweight;   Cardiovascular Diseases;   Chronic Kidney Disease
Interventions:   Drug: Orforglipron;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Not yet recruiting
https://ift.tt/KbvUhxl